Study of inhaled GDC-6988 for mucus lung diseases
Part of Lungs & breathing clinical trials.
This study tests an inhaled medicine (GDC-6988) to see if it is safe and helps clear mucus from the lungs in people with mucus-related lung diseases like chronic bronchitis, COPD, or bronchiectasis. You may qualify if your lung function is fairly stable and you produce daily mucus.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a lung condition with too much mucus, like chronic bronchitis, bronchiectasis, or COPD
- Your lung function (FEV1) is at least 40% of what's expected for your age and height
- Your condition has been stable for the past 28 days (no sudden flare-ups or infections)
- You are on a stable set of medicines for your lungs for at least 28 days and willing to stay on them
- For some parts of the study: you produce at least a teaspoon of mucus daily and can provide a sputum (mucus) sample
- You are not currently pregnant, breastfeeding, or planning to become pregnant
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an inhaled medication called CSL787 to see if it can help people with non-cystic fibrosis bronchiectasis (a lung condition that causes frequent infections and breathing problems). The study looks at different doses and checks how well the drug works and if it is safe.
This study tests a new medication called Galvokimig to see if it helps reduce lung infections and improve quality of life in adults with bronchiectasis (a condition where lung airways are damaged and fill with mucus). It is a 24 to 52 week treatment, and you will be monitored closely for safety and effectiveness.
This trial tests a new medicine, HSK31858, for people with non-cystic fibrosis bronchiectasis (a lung condition causing chronic cough and infections). It aims to see if the drug reduces lung flare-ups and improves symptoms.
This study tests how safe an experimental inhaled medicine (HSK31858) is for people with non-cystic fibrosis bronchiectasis, a lung condition where airways are damaged and collect mucus. You can only join if you already completed a previous HSK31858 study.
This study looks at the bacteria in the lungs, infection patterns, and CT scan findings in people with COPD, asthma, or bronchiectasis. It aims to understand these conditions better and may help guide future treatments.
This study looks at different types of bronchiectasis in Chinese patients to understand the disease better. It may involve additional tests like lung function and questionnaires.
Hear when a new Non-cystic Fibrosis Bronchiectasis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.